000130265 001__ 130265 000130265 005__ 20240124152850.0 000130265 0247_ $$2doi$$a10.1007/s00268-011-1078-7 000130265 0248_ $$2sideral$$a73978 000130265 037__ $$aART-2011-73978 000130265 041__ $$aeng 000130265 100__ $$0(orcid)0000-0002-8275-7191$$aGarcía-Gil, F. A.$$uUniversidad de Zaragoza 000130265 245__ $$aCelsior Versus University of Wisconsin Preserving Solutions for Liver Transplantation: Postreperfusion Syndrome and Outcome of a 5-Year Prospective Randomized Controlled Study 000130265 260__ $$c2011 000130265 5203_ $$aBackground: Celsior solution (CS) is a high-sodium, low-potassium, low-viscosity extracellular solution that has been used for liver graft preservation in recent years, although experience with it is still limited. We performed an open-label randomized active-controlled trial comparing CS with the University of Wisconsin solution (UW) for liver transplantation (LT), with a follow-up period of 5 years. Methods: Adult transplant recipients (n = 102) were prospectively randomized to receive either CS (n = 51) or UW (n = 51). The two groups were comparable with respect to donor and recipient characteristics. The primary outcome measure was the incidence of postreperfusion syndrome (PRS). Secondary outcome measures included primary nonfunction (PNF) or primary dysfunction (PDF), liver retransplantation, and graft and patient survival. Other secondary outcome measures were days in the intensive care unit (ICU) and the rates of acute rejection, chronic rejection, infectious complications, postoperative reoperations, and vascular and biliary complications. Results In all, 14 posttransplant variables revealed no significant differences between the groups. There were no cases of PNF or PDF. The incidence of PRS was 5.9% in the CS group and 21.6% in the UW group (P = 0.041). After reperfusion, CS revealed greater control of serum potassium (P = 0.015), magnesium levels (P = 0.005), and plasma glucose (P = 0.042) than UW. Respective patient survivals at 3, 12, and 60 months were 95.7, 87.2, and 82.0% for the CS group and 95.7, 83.3, and 66.6% for the UW group (P = 0.123). Conclusions While retaining the same degree of safety and effectiveness as UW for LT, CS may yield postliver graft reperfusion benefits, as shown in this study by a significant reduction in the incidence of PRS and greater metabolic control. 000130265 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000130265 590__ $$a2.362$$b2011 000130265 591__ $$aSURGERY$$b48 / 199 = 0.241$$c2011$$dQ1$$eT1 000130265 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000130265 700__ $$0(orcid)0000-0002-7119-2244$$aSerrano, M. T. 000130265 700__ $$0(orcid)0000-0003-2656-6750$$aFuentes-Broto, L.$$uUniversidad de Zaragoza 000130265 700__ $$aArenas, J. 000130265 700__ $$0(orcid)0000-0001-9507-6478$$aGarcía, J. J.$$uUniversidad de Zaragoza 000130265 700__ $$0(orcid)0000-0002-4437-2581$$aGüemes, A.$$uUniversidad de Zaragoza 000130265 700__ $$aBernal, V. 000130265 700__ $$aCampillo, A. 000130265 700__ $$aSostres, C. 000130265 700__ $$0(orcid)0000-0001-6033-2216$$aAraiz, J. J.$$uUniversidad de Zaragoza 000130265 700__ $$aRoyo, P. 000130265 700__ $$aSimón, M. A. 000130265 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología 000130265 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000130265 7102_ $$11004$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Cirugía 000130265 773__ $$g35, 7 (2011), 1598-1607$$pWorld j. surg.$$tWORLD JOURNAL OF SURGERY$$x0364-2313 000130265 8564_ $$s337462$$uhttps://zaguan.unizar.es/record/130265/files/texto_completo.pdf$$yVersión publicada 000130265 8564_ $$s2268698$$uhttps://zaguan.unizar.es/record/130265/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000130265 909CO $$ooai:zaguan.unizar.es:130265$$particulos$$pdriver 000130265 951__ $$a2024-01-24-14:58:06 000130265 980__ $$aARTICLE